Taysha Gene Therapies, Inc. TSHA Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $276.58M-13.5% | $319.77M+7.5% | $297.34M-4.9% | $312.76M+168% | $116.59M-16.1% | ||
| $282.25M-13.1% | $324.65M+8.2% | $299.95M-5.2% | $316.26M+162% | $120.71M-15.1% | ||
| $6.45M-4.2% | $6.74M-1.0% | $6.81M-2.2% | $6.96M-3.9% | $7.24M-3.3% | ||
| $300.35M-12.5% | $343.32M+8.5% | $316.55M-5.0% | $333.33M+141% | $138.36M-13.7% | ||
| $4.56M-27.3% | $6.28M+15.4% | $5.44M-29.5% | $7.71M+78.3% | $4.33M+20.4% | ||
| —— | —— | $5.49M0.0% | $5.49M-26.6% | $7.47M-23.6% | ||
| $20.1M-24.3% | $26.55M-7.3% | $28.63M+12.9% | $25.35M+12.4% | $22.56M-14.0% | ||
| $48.96M-2.3% | $50.11M-1.5% | $50.85M+23.9% | $41.05M-3.3% | $42.45M-3.4% | ||
| $88.41M-8.3% | $96.38M-1.2% | $97.57M+15.3% | $84.6M+1.6% | $83.3M-6.2% | ||
| $3K0.0% | $3K0.0% | $3K0.0% | $3K+50.0% | $2K0.0% | ||
| -$753.71M-6.0% | -$711.3M-4.1% | -$683.45M-5.0% | -$650.72M-4.3% | -$623.83M-3.6% | ||
| $211.94M-14.2% | $246.94M+12.8% | $218.99M-12.0% | $248.73M+352% | $55.06M-23.0% | ||
| $300.35M-12.5% | $343.32M+8.5% | $316.55M-5.0% | $333.33M+141% | $138.36M-13.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Taysha Gene Therapies, Inc. cover its short-term obligations?
- Its current ratio is 14.04 — current assets exceed current liabilities.
- Where does Taysha Gene Therapies, Inc.'s balance sheet data come from?
- Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.